Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.

Cells - 17 Aug 2021

Murnyak Balazs, Huang L Eric

Abstract excerpt

Since the initial discovery of recurrent isocitrate dehydrogenase 1 (IDH1) mutations at Arg132 in glioma, IDH1 hotspot mutations have been identified in cholangiocarcinoma, chondrosarcoma, leukemia, and various other types of cancer of sporadic incidence. Studies in glioma and leukemia have helped promote the theory that IDH1 mutations are an oncogenic event that drives tumorigenesis in general. Through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cancer, Hypoxia, and Metabolism
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma Diagnosis and Treatment

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Organ Specificity

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 34440884
DOI: 10.3390/cells10082116
PMCID: PMC8394030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.PMID 34440884Read ↗

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.Semantic proximity Read ↗

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.Semantic proximity Read ↗

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas.Semantic proximity Read ↗

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomasSemantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Semantic proximity Read ↗

Clinical and Molecular Features of Patients with Gliomas Harboring Idh1 Non-Canonical Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer DatabaseSemantic proximity Read ↗

Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.Semantic proximity Read ↗

IDH1 Non-Canonical Mutations and Survival in Patients with GliomaSemantic proximity Read ↗

IDH1 <sup>R132H</sup> acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.